Scynexis (SCYX) Retained Earnings (2013 - 2026)
Scynexis (SCYX) posted Retained Earnings of -$406.4 million for Q1 2026, down 193.54% on a QoQ basis from $434.5 million in Q4 2025, and down 193.98% year-over-year from $432.4 million in Q1 2025.
Scynexis (SCYX) Retained Earnings (2013 - 2026) Analysis & Trends
Scynexis' Retained Earnings history runs 14 years deep, the most recent figure standing at -$406.4 million for Q1 2026.
- Quarterly Retained Earnings fell 193.98% year-over-year to -$406.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$406.4 million (down 193.98% YoY) and the FY2025 annual result came in at $434.5 million, up 0.67% from the prior year.
- Retained Earnings was -$406.4 million for Q1 2026 at Scynexis, down from $434.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $434.5 million in Q4 2025 and bottomed at -$456.2 million in Q1 2023.
- A 5-year average of -$100.1 million and a median of -$364.9 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 221.48% — and 2026, when it tumbled 193.98%.
- Scynexis' Retained Earnings stood at -$422.3 million in 2022, then increased by 15.88% to -$355.2 million in 2023, then surged by 221.48% to $431.6 million in 2024, then climbed by 0.67% to $434.5 million in 2025, then tumbled by 193.54% to -$406.4 million in 2026.
- Business Quant data shows SCYX's Retained Earnings at -$406.4 million in Q1 2026, $434.5 million in Q4 2025, and -$397.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | -406.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -406.40 Mn |
| Dec 31, 2025 | 434.47 Mn |
| Sep 30, 2025 | -397.40 Mn |
| Jun 30, 2025 | -388.81 Mn |
| Mar 31, 2025 | 432.42 Mn |
| Dec 31, 2024 | 431.57 Mn |
| Sep 30, 2024 | -372.10 Mn |
| Jun 30, 2024 | 429.66 Mn |
| Mar 31, 2024 | 428.90 Mn |
| Dec 31, 2023 | -355.25 Mn |
| Sep 30, 2023 | -335.70 Mn |
| Jun 30, 2023 | 426.94 Mn |
| Mar 31, 2023 | -456.16 Mn |
| Dec 31, 2022 | -422.29 Mn |
| Sep 30, 2022 | -407.90 Mn |
| Jun 30, 2022 | -378.28 Mn |
| Mar 31, 2022 | -364.93 Mn |
| Dec 31, 2021 | -359.48 Mn |
| Sep 30, 2021 | -330.20 Mn |
| Jun 30, 2021 | -329.63 Mn |